GlassScriptPhysician profile
Katherine Tabori
NPI 1518089291
$3,150.26
in general payments reported to CMS, 2019-2025
31 companies · $576 in 2025
The $576 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $793 · 2020: $151 · 2022: $128 · 2023: $783 · 2024: $720 · 2025: $576.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,078.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,077.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $554.78 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $396.93 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $280.01 | 2023-2025 | Ubrelvy, Qulipta, Vraylar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $265.20 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $263.18 | 2019-2025 | Airsupra |
| Abbott Laboratories | $147.53 | 2023-2024 | Freestyle Libre 3, Freestyle Libre 2, Proclaim |
| Pfizer INC. | $141.21 | 2019-2025 | |
| Astellas Pharma US INC | $136.68 | 2019-2025 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $123.01 | 2019-2022 | |
| Exact Sciences Corporation | $119.09 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $106.13 | 2019-2025 | Repatha, Otezla, Evenity |
| Otsuka America Pharmaceutical, INC. | $71.90 | 2023-2024 | Rexulti, Nuedexta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $67.66 | 2019-2025 | Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $49.20 | 2019-2024 | Shingrix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $40.15 | 2025 | Caplyta |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $39.05 | 2022-2023 | |
| Idorsia Pharmaceuticals US INC | $35.19 | 2023 | Quviviq |
| Merck Sharp & Dohme LLC | $34.89 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $34.45 | 2024 | |
| Xeris Pharmaceuticals, INC. | $34.17 | 2022-2023 | Gvoke Hypopen |
| Corcept Therapeutics | $31.53 | 2025 | Korlym |
| Janssen Pharmaceuticals, INC | $26.55 | 2019-2020 | |
| Adlon Therapeutics L.P. | $23.81 | 2019 | |
| Phadia US INC. | $22.66 | 2019 | |
| Dynavax Technologies Corporation | $19.85 | 2025 | Heplisav-B |
| Phathom Pharmaceuticals, INC. | $17.02 | 2025 | Voquezna |
| Antares Pharma, INC. | $15.82 | 2019 | |
| Valeritas, INC. | $14.25 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $13.92 | 2019 | |
| Insulet Corporation | $12.43 | 2019 | |
| Amarin Pharma, INC. | $12.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Tabori listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.